Yazen Alnouti

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4308656/publications.pdf

Version: 2024-02-01

60	2,661	236833	189801
papers	citations	25 h-index	50 g-index

61	61	61	4001
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Direct Comparison of Chol-siRNA Polyplexes and Chol-DsiRNA Polyplexes Targeting STAT3 in a Syngeneic Murine Model of TNBC. Non-coding RNA, 2022, 8, 8.	1.3	0
2	Analyte recovery in LC-MS/MS bioanalysis: An old issue revisited. Analytica Chimica Acta, 2022, 1198, 339512.	2.6	1
3	Urinary BA Indices as Prognostic Biomarkers for Complications Associated with Liver Diseases. International Journal of Hepatology, 2022, 2022, 1-17.	0.4	0
4	Small-molecule IKKÎ² activation modulator (IKAM) targets MAP3K1 and inhibits pancreatic tumor growth. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2115071119.	3.3	3
5	The selective PPAR-delta agonist seladelpar reduces ethanol-induced liver disease by restoring gut barrier function and bile acid homeostasis in mice. Translational Research, 2021, 227, 1-14.	2.2	13
6	Discovery, synthesis and biological characterization of a series of N-(1-(1,1-dioxidotetrahydrothiophen-3-yl)-3-methyl-1H-pyrazol-5-yl)acetamide ethers as novel GIRK1/2 potassium channel activators. RSC Medicinal Chemistry, 2021, 12, 1366-1373.	1.7	0
7	Bile acid indices as biomarkers for liver diseases I: Diagnostic markers. World Journal of Hepatology, 2021, 13, 433-455.	0.8	4
8	Preliminary preclinical study of Chol-DsiRNA polyplexes formed with PLL[30]-PEG[5K] for the RNAi-based therapy of breast cancer. Nanomedicine: Nanotechnology, Biology, and Medicine, 2021, 33, 102363.	1.7	4
9	Bile acid indices as biomarkers for liver diseases II: The bile acid score survival prognostic model. World Journal of Hepatology, 2021, 13, 543-556.	0.8	3
10	Lipophilic nanocrystal prodrug-release defines the extended pharmacokinetic profiles of a year-long cabotegravir. Nature Communications, 2021, 12, 3453.	5.8	29
11	Intramuscular and subcutaneous administration of antiretroviral drugs, compared with oral, enhances delivery to lymphoid tissues in BALB/c mice. Journal of Antimicrobial Chemotherapy, 2021, 76, 2651-2658.	1.3	10
12	Transformation of tenofovir into stable ProTide nanocrystals with long-acting pharmacokinetic profiles. Nature Communications, 2021, 12, 5458.	5.8	26
13	Direct and indirect quantification of phosphate metabolites of nucleoside analogs in biological samples. Journal of Pharmaceutical and Biomedical Analysis, 2020, 178, 112902.	1.4	6
14	A combination of Omega-3 PUFAs and COX inhibitors: A novel strategy to manage obesity-linked dyslipidemia and adipose tissue inflammation. Journal of Diabetes and Its Complications, 2020, 34, 107494.	1.2	10
15	KVA-D-88, a Novel Preferable Phosphodiesterase 4B Inhibitor, Decreases Cocaine-Mediated Reward Properties in Vivo. ACS Chemical Neuroscience, 2020, 11, 2231-2242.	1.7	8
16	Head-to-head comparative pharmacokinetic and biodistribution (PK/BD) study of two dexamethasone prodrug nanomedicines on lupus-prone NZB/WF1 mice. Nanomedicine: Nanotechnology, Biology, and Medicine, 2020, 29, 102266.	1.7	4
17	The Synergistic Effect of an ATP-Competitive Inhibitor of mTOR and Metformin on Pancreatic Tumor Growth. Current Developments in Nutrition, 2020, 4, nzaa131.	0.1	6
18	Synthesis and SAR Studies of 1H-Pyrrolo[2,3-b]pyridine-2-carboxamides as Phosphodiesterase 4B (PDE4B) Inhibitors. ACS Medicinal Chemistry Letters, 2020, 11, 1848-1854.	1.3	14

#	Article	IF	Citations
19	A year-long extended release nanoformulated cabotegravir prodrug. Nature Materials, 2020, 19, 910-920.	13.3	66
20	Synthesis of a long acting nanoformulated emtricitabine ProTide. Biomaterials, 2019, 222, 119441.	5.7	15
21	Assessing the lymphoid tissue bioavailability of antiretrovirals in human primary lymphoid endothelial cells and in mice. Journal of Antimicrobial Chemotherapy, 2019, 74, 2974-2978.	1.3	24
22	A long acting nanoformulated lamivudine ProTide. Biomaterials, 2019, 223, 119476.	5.7	24
23	Creation of a long-acting rilpivirine prodrug nanoformulation. Journal of Controlled Release, 2019, 311-312, 201-211.	4.8	22
24	Synthesis and characterization of a long-acting emtricitabine prodrug nanoformulation . International Journal of Nanomedicine, 2019, Volume 14, 6231-6247.	3.3	16
25	Discovery, synthesis and characterization of a series of (1-alkyl-3-methyl-1H-pyrazol-5-yl)-2-(5-aryl-2H-tetrazol-2-yl)acetamides as novel GIRK1/2 potassium channel activators. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 791-796.	1.0	6
26	Pharmacokinetic testing of a first-generation cabotegravir prodrug in rhesus macaques. Aids, 2019, 33, 585-588.	1.0	8
27	Creation of a long-acting nanoformulated dolutegravir. Nature Communications, 2018, 9, 443.	5.8	101
28	Simultaneous quantification of intracellular lamivudine and abacavir triphosphate metabolites by LCâ€“MS/MS. Journal of Pharmaceutical and Biomedical Analysis, 2018, 153, 248-259.	1.4	13
29	Optimizing the preparation and stability of decorated antiretroviral drug nanocrystals. Nanomedicine, 2018, 13, 871-885.	1.7	21
30	Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profiles. Biomaterials, 2018, 151, 53-65.	5.7	77
31	Pharmacokinetics of a Long-Acting Nanoformulated Dolutegravir Prodrug in Rhesus Macaques. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	30
32	Simultaneous LCâ€“MS/MS analysis of eicosanoids and related metabolites in human serum, sputum and BALF. Biomedical Chromatography, 2018, 32, e4102.	0.8	26
33	Modulation of the intestinal bile acid/farnesoid X receptor/fibroblast growth factor 15 axis improves alcoholic liver disease in mice. Hepatology, 2018, 67, 2150-2166.	3.6	189
34	Increased glycine-amidated hyocholic acid correlates to improved early weight loss after sleeve gastrectomy. Surgical Endoscopy and Other Interventional Techniques, 2018, 32, 805-812.	1.3	14
35	Species differences in bile acids I. Plasma and urine bile acid composition. Journal of Applied Toxicology, 2018, 38, 1323-1335.	1.4	81
36	Species differences in bile acids II. Bile acid metabolism. Journal of Applied Toxicology, 2018, 38, 1336-1352.	1.4	41

#	Article	IF	Citations
37	A combination of dietary N-3 fatty acids and a cyclooxygenase-1 inhibitor attenuates nonalcoholic fatty liver disease in mice. Journal of Nutritional Biochemistry, 2017, 42, 149-159.	1.9	4
38	Leveraging of Rifampicin-Dosed Cynomolgus Monkeys to Identify Bile Acid 3-O-Sulfate Conjugates as Potential Novel Biomarkers for Organic Anion-Transporting Polypeptides. Drug Metabolism and Disposition, 2017, 45, 721-733.	1.7	38
39	Pharmacokinetic and Biodistribution Studies of HPMA Copolymer Conjugates in an Aseptic Implant Loosening Mouse Model. Molecular Pharmaceutics, 2017, 14, 1418-1428.	2.3	26
40	Harmonizing lipidomics: NIST interlaboratory comparison exercise for lipidomics using SRM 1950â€“Metabolites in Frozen Human Plasma. Journal of Lipid Research, 2017, 58, 2275-2288.	2.0	312
41	Development and characterization of a long-acting nanoformulated abacavir prodrug. Nanomedicine, 2016, 11, 1913-1927.	1.7	41
42	Quantitative analysis of endogenous compounds. Journal of Pharmaceutical and Biomedical Analysis, 2016, 128, 426-437.	1.4	170
43	Urinary Bile Acids as Biomarkers for Liver Diseases I. Stability of the Baseline Profile in Healthy Subjects. Toxicological Sciences, 2015, 143, 296-307.	1.4	49
44	Impaired synaptic development in a maternal immune activation mouse model of neurodevelopmental disorders. Brain, Behavior, and Immunity, 2015, 50, 249-258.	2.0	71
45	Urinary Bile Acids as Biomarkers for Liver Diseases II. Signature Profiles in Patients. Toxicological Sciences, 2015, 143, 308-318.	1.4	33
46	Pharmacokinetics, Biodistribution, and Toxicity of Folic Acid-Coated Antiretroviral Nanoformulations. Antimicrobial Agents and Chemotherapy, 2014, 58, 7510-7519.	1.4	21
47	Nod2 deficiency protects mice from cholestatic liver disease by increasing renal excretion of bile acids. Journal of Hepatology, 2014, 60, 1259-1267.	1.8	28
48	The profile of bile acids and their sulfate metabolites in human urine and serum. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2013, 942-943, 53-62.	1.2	95
49	Preclinical Pharmacokinetics and Tissue Distribution of Long-Acting Nanoformulated Antiretroviral Therapy. Antimicrobial Agents and Chemotherapy, 2013, 57, 3110-3120.	1.4	70
50	Simultaneous characterization of bile acids and their sulfate metabolites in mouse liver, plasma, bile, and urine using LCâ€“MS/MS. Journal of Pharmaceutical and Biomedical Analysis, 2011, 55, 1111-1119.	1.4	110
51	UPLCâ€“MS/MS quantification of nanoformulated ritonavir, indinavir, atazanavir, and efavirenz in mouse serum and tissues. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2011, 879, 2332-2338.	1.2	33
52	Mechanisms of gender-specific regulation of mouse sulfotransferases (Sults). Xenobiotica, 2011, 41, 187-197.	0.5	45
53	Bile Acid Sulfation: A Pathway of Bile Acid Elimination and Detoxification. Toxicological Sciences, 2009, 108, 225-246.	1.4	304
54	Substrate specificity of rat Na + /taurocholate cotransporting polypeptide. FASEB Journal, 2009, 23, 747.5.	0.2	0

#	Article	IF	Citations
55	Characterization of a stable cell line expressing human Na + /taurocholate cotransporting polypeptide for high throughput screening. FASEB Journal, 2009, 23, 796.12.	0.2	0
56	Quantitative-profiling of bile acids and their conjugates in mouse liver, bile, plasma, and urine using LCâ€“MS/MS. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2008, 873, 209-217.	1.2	223
57	Simultaneous determination of zidovudine and lamivudine from rat tissues by liquid chromatography/tandem mass spectrometry. Rapid Communications in Mass Spectrometry, 2005, 19, 503-508.	0.7	20
58	Simultaneous quantitation of zidovudine and zidovudine monophosphate from plasma, amnioticï¬‚uid and tissues by micellar capillary electrophoresis. Biomedical Chromatography, 2004, 18, 523-531.	0.8	8
59	Simultaneous determination of zidovudine and lamivudine from rat plasma, amniotic ?uid and tissues by HPLC. Biomedical Chromatography, 2004, 18, 641-647.	0.8	25
60	Determination of lamivudine in plasma, amniotic fluid, and rat tissues by liquid chromatography. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2004, 803, 279-284.	1.2	20